ImmuneOncia Therapeutics, Inc. (CEO Heung-Tae Kim) announced interim results today from the ongoing Phase 1b clinical trial of its next-generation CD47-targeting antibody, IMC-002, in combination with ...

In a report released on May 30, analyst Jason McCarthy from Maxim Group maintained a Buy rating on CERo Therapeutics Holdings ...

Detailed price information for Vigil Neuroscience Inc (VIGL-Q) from The Globe and Mail including charting and trades.

Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer's disease to the neurology pipeline Paris, May 22, 2025. Sanofi announced today that it has entered ...

BDC-4182 Phase 1 dose-escalation study now open for enrollmentBDC-3042 Phase 1 dose-escalation data presented at AACR 2025 demonstrated a favorable safety profile, dose-dependent biological activity ...

Zanidatamab was previously approved by the U.S. Food and Drug Administration (FDA) in November 2024 and had a positive ...

Clinical trials refer to medical research that involves testing new treatments on people. The four phases help to ensure the ...

Palliative care starts with building a relationship between the patient, the family, and their care team. Learn why timing ...

The question of how life could have emerged is one of the most long-standing mysteries in science. In a new study, the ...

In its first global phase 3 readout, Akeso and Summit Therapeutics’ closely watched PD-1xVEGF bispecific antibody ivonescimab ...